Wednesday 30 July 2014

Sanofi, Regeneron cholesterol drug may cut heart risk, trial hints


The Sanofi Pasteur logo is seen at the entrance of a building at tthe French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile By Ransdell Pierson and Natalie Huet NEW YORK/PARIS (Reuters) - A new drug being developed by Sanofi SA and Regeneron Pharmaceuticals Inc significantly cut cholesterol in nine late-stage clinical trials, the companies said on Wednesday, and provided the first glimpse of its potential to prevent heart attacks and strokes. The injectable drug, alirocumab, is from a new class of medicines called PCSK9 inhibitors, which are also being developed by Amgen Inc and Pfizer Inc. If approved, they could lower "bad" LDL cholesterol in a new way and reap multibillion-dollar sales. An interim safety analysis of one of the Phase III studies showed patients on alirocumab were less prone, versus those on placebo, to a combination of cardiovascular events, including cardiac death, heart attack, stroke, and chest pain requiring hospitalization.








via Health News Headlines - Yahoo News Read More Here..


Lake forest health and fitness http://ift.tt/1ocn6fh

No comments:

Post a Comment